NCT05700071
MRS of Glioma Genomics
Recruiting · Not Applicable · Institut National de la Santé Et de la Recherche Médicale, France · registry updated 2026-07-08
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
In France, about 5000 new people with a primary malignant brain tumor are diagnosed each year. The most common primary tumors are gliomas, originating from glial cells (astrocytomas and oligodendrogliomas). Low-grade gliomas are mildly aggressive, but they often evolve into a more malignant form. Mutations in the genes encoding isocitrate dehydrogenase (IDH) are found in about 80% of low-grade gliomas and are associated with a favorable prognosis. Remarkably, IDH-mutated gliomas are characterized by a specific cellular metabolism causing the accumulation of D-2-hydroxyglutarate (2HG) in tumor cells. 2HG can be detected in vivo using 1H magnetic resonance spectroscopy (MRS) and is recognized as a unique, noninvasive biomarker of IDH-mutated gliomas. Noninvasive detection of IDH mutations via 2HG MRS represents a crucial step for decision-making and patient care. A subset of IDH-mutated tumors also presents a complete deletion of 1p and 19q chromosome arms (1p/19q codeletion). The 1p/19q codeletion is specifically linked to the oligodendroglial histologic subtype and it has been associated with a better patient outcome....
Inclusion
- Inclusion Criteria :
- Affiliations to a social security scheme (as a beneficiary or a person entitled to benefits)
- Obtainig written, informed consent
- One of the following two situations
- Group 1 : Probable grade II/III/IV glioma, for which excision is scheduled.
- Group 2 : Histologically confirmed grade II or III glioma with known IDH1/IDH2 status, which has received no treatment other than surgery and is due to undergo therapy other than surgery.
Exclusion
- Containdications to MRI : Pacemaker or neural stimulators, intraocular or intracerebral metallic foreign bodies, cochlear implant, heart valve or metallic surgical arterial devices that are not MRI ompatible, metallic devices susceptible to concentrating radio-frequency pulses, claustrophobia
- Pregnant or breastfeeding women
- Regulatory criteria :
- Pregnant women, women in labor, breastfeeding women ; Failure to sign the consent form or paticipant refusal ; Legal protection measures (guardianship, curatorship, judicial protection) ; Participation in another research study that does not allow for compliance with the exclusion period between the two studies ; Individuals not covered by a health insurance scheme.